Sanai Health Industry Group Company Limited
HHKEX:18890.16
HKD
+0.01
(+5.96%)
Sanai Health Industry Group Company Limited
HKEX:1889
(Hong Kong Exchange)
Recent
price
0.16
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Sanai Health Industry Group Company Limited is a diversified investment holding group engaged in the development, manufacturing, marketing and sale of pharmaceutical products; provision of finance leasing services; and genetic testing and molecular diagnostic services (discontinued during 2024). The company operates through three principal segments: Pharmaceutical Products, Finance Leasing, and Genetic Testing and Molecular Diagnostic Services, with activities spanning development, manufacturing, distribution, and related software and consulting services. Latest major company changes include: disposal of a subsidiary stake through a 99% equity interest sale in a target company for approximately RMB 18.69 million, announced in November 2025, as part of a strategic portfolio optimization; interim and annual reporting in 2025 reflecting ongoing cost controls and a material decline in profitability in prior years; strategic review leading to potential regrouping of business segments and reassessment of non-core asset holdings; and ongoing legal and regulatory matters related to lease arrangements and court proceedings impacting cash flows. These developments accompany the company’s stated focus on core pharmaceutical product activities while simplifying its non-core financial assets and operational footprint. Additional context: The company is active in the Greater China region, with operations in mainland China and Hong Kong, and maintains relationships with suppliers, distributors, and healthcare providers in these markets. It is listed on the Hong Kong Stock Exchange under the ticker 1889.HK, with headquarters in Hong Kong and principal executive offices in Beijing, China. The group has historically included subsidiaries involved in branded and generic pharmaceutical products, software sales related to pharmaceutical activities, and finance leasing services; a genetic testing and molecular diagnostics division exists in the portfolio, with the latter being discontinued in 2024. The business has undergone reorganizations and asset disposals over the last 1–2 years as part of strategic realignment. Founding year and headquarters: established in the late 1990s (historical listing context indicates formation prior to 2000) with headquarters in Hong Kong, and significant operations in mainland China. Subsidiaries and parent relationships include Beijing Hangyang Health Technology Co., Ltd. as a key subsidiary involved in some holdings and transactions; and Beijing Hangyang Health-related entities referenced in recent disposals. The group has pursued strategic partnerships and asset disposals to streamline operations and focus on core pharmaceutical activities.